ClinicalTrials.gg
CompletedNCT03649971Updated Feb 3, 2025

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

A Phase 1 interventional study of Guselkumab and Placebo in Adenomatous Polyposis Coli, sponsored by Janssen Research & Development, LLC. Completed at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.

Enrollment
9th of 27
77 · median 42
Started
2018
the only one that year
Phase 1
6 of 39
1 open now
Registered
23rd of 39
by date
Lead sponsor
2 of 39
Janssen Research & Development, LLC

Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 1, and was the 23rd registered.

Adenomatous Polyposis Coli

92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.

Browse Adenomatous Polyposis Coli studies →

Open to participants now

12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Adenomatous Polyposis Coli with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.

Read the detailed description

Familial adenomatous polyposis (FAP) is the most common polyposis syndrome. It is autosomal dominant inherited disorder characterized by early onset of hundreds to thousands of adenomatous polyps throughout colon. If left untreated, this syndrome may develop colorectal cancer (CRC). Polyps from individuals with FAP display inflammatory features associated with activation of interleukin (IL) 23/IL 17/JAK/STAT3 pathway. This inflammation is thought to contribute to further mutagenesis, culminating in tumor development. Specifically, IL-23 is linked to tumor growth and progression in CRC. Guselkumab is a human immunoglobulin monoclonal antibody directed against p19 subunit of IL-23, specifically targets IL-23 and inhibits its interaction with IL-23 receptor, inhibiting IL 23 specific intracellular signaling and subsequent cell activation and cytokine production, which result in less inflammation and reduce tumor development. The clinical hypothesis of this study is that treatment with guselkumab will reduce rectal/pouch polyp burden compared with baseline in active arms compared with placebo. The study is designed to determine if guselkumab has clinical activity in colorectum and duodenum, by reducing number of polyps over a period of 24 weeks. Participants will be randomized to 1 of 3 treatment arms (Guselkumab 100 mg [milligram] SC [subcutaneous], Guselkumab 300 mg SC, and placebo SC). Efficacy evaluations include rectal/pouch polyp burden assessment, biomarker analysis include discrete IL-23 signaling effector proteins (IL-23R, pSTAT3, Il-17A) and safety evaluations will include monitoring of adverse events, laboratory tests, vital sign measurements, and physical examination. Safety will be monitored throughout study (up to Week 60).

03

Conditions studied

  • Adenomatous Polyposis Coli
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC) germline mutation with or without family history, or with greater than (>)100 adenomas in large intestine and a family history of FAP, attenuated FAP is allowed. FAP phenotype post colectomy for polyposis with a family history of FAP may be allowed
  • Post-colectomy or subtotal colectomy
  • Polyps with a sum of diameters greater than or equal to (>=)10 millimeter (mm) in the rectum or pouch on at screening
  • A woman of must agree not to get pregnant during the study and at least 12 weeks after the last dose of study administration
  • A woman must agree not to breast feed or donate eggs (ova, oocytes) during the study and for a period of 12 weeks after the last administration of study drug

Exclusion criteria

Exclusion Criteria:

  • Prior use of any biologic therapy targeting interleukin (IL)-12/23, IL-17, or IL-23 receptor
  • Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The use 100 milligram (mg) of aspirin a day or 700 mg of aspirin per week is allowed
  • Treatment with other FAP-directed drug therapy (including NSAID [Nonsteroidal anti-inflammatory drug] drugs), unless completes a 4-week prior to randomization
  • High grade dysplasia or cancer on at screening in GI tract (including stomach, duodenum, and colon/rectum/pouch)
  • Duodenal, colorectal, or pouch polyp: >2 centimeter (cm) unless excised at the screening evaluation; and 1 to 2 cm with evidence of high-grade dysplasia upon biopsy unless excised
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Guselkumab Dose 1

    Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.

    Drug: Guselkumab

  • Experimental
    Guselkumab Dose 2

    Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.

    Drug: Guselkumab

  • Placebo comparator
    Placebo

    Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.

    Drug: Placebo

Interventions

  • Guselkumab SC will be administered every 4 weeks.

    Also known as: Tremfya

  • DrugPlacebo

    Placebo SC will be administered every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24

    Percentage change from baseline in rectal/pouch polyp burden (sum of the polyp diameters) at Week 24 will be determined through endoscopy.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage Change from Baseline in Number of Colorectal Polyps

    Percentage change from baseline in number of colorectal polyps will be determined.

    Time frame: Baseline, Weeks 24 and 52

  2. Percentage Change from Baseline in Number of J-pouch Polyps

    Percentage change from baseline in number of J-pouch polyps will be determined.

    Time frame: Baseline, Weeks 24 and 52

  3. Percentage Change from Baseline in J-pouch Polyp Burden

    Percentage change from baseline in J-pouch polyp burden (sum of polyp diameters) will be determined.

    Time frame: Baseline, Weeks 24 and 52

  4. Percentage Change from Baseline in Number of Duodenal Polyps

    Percentage change from baseline in number of duodenal polyps will be determined.

    Time frame: Baseline, Weeks 24 and 52

  5. Percentage Change from Baseline in Duodenal Polyp Burden

    Percentage change from baseline in duodenal polyp burden (sum of polyp diameters) will be determined.

    Time frame: Baseline, Weeks 24 and 52

  6. Change in International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage

    Change in InSiGHT stage will be determined. Various stages of InSiGHT staging system are defined as: Stage 0: 0-10 polyps, all less than (\<)5 millimeter (mm); Stage 1: 10-25 polyps, most \< 5 mm, none greater than (\>) 1 centimeter (cm); Stage 2: 10-25 polyps, any \> 1 cm, amenable to complete removal; Stage 3: \> 25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of High-Grade Dysplasia (HGD), even if completely excised; and Stage 4: \> 25 polyps amenable to complete removal, or any incompletely excised sessile polyp showing HGD, any invasive cancer).

    Time frame: Baseline, Weeks 24 and 52

  7. Change in Spigelman Stage Score

    Change in Spigelman stage score will be determined. Spigelman classification system measures risk of developing duodenal cancer in familial adenomatous polyposis (FAP). It has been classified in following stages- Stage 0 (0 points); Stage 1 (1-4 points); Stage 2 (5-6 points); Stage 3 (7-8 points); and Stage 4 (9-12 points). The total score ranges from 0 to 12. Points are accumulated for polyps' number, size, histology and severity of dysplasia. Stage 1 indicates mild disease, whereas stage 3-4 indicates severe duodenal polyposis.

    Time frame: Baseline, Weeks 24 and 52

  8. Trough Concentration of Guselkumab

    Serum samples will be analyzed to determine trough concentrations of guselkumab using a validated specific, and sensitive method.

    Time frame: Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48

  9. Number of Participants with Anti-guselkumab Antibodies

    Number of participants with Anti-guselkumab antibodies will be determined.

    Time frame: Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48

  10. Anti-guselkumab Antibodies Serum Titers

    Serum samples will be screened for antibodies binding to guselkumab and the titer of confirmed positive samples will be reported.

    Time frame: Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48

  11. Number of Participants with Adverse Events as a Measure of Safety

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: From Screening up to 60 Weeks

  12. Number of Participants with Vital Sign Abnormalities as a Measure of Safety and Tolerability

    Number of participants with vital sign abnormalities will be reported. Vital signs includes temperature, pulse/heart rate, respiratory rate and blood pressure.

    Time frame: From Screening up to 52 Weeks

  13. Number of Participants with Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability

    Number of participants with clinical laboratory abnormalities will be reported. Blood samples for serum chemistry and hematology will be collected at predefined time points for clinical laboratory testing.

    Time frame: From Screening up to 52 Weeks

  14. Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue

    Relative Changes to Baseline in levels of IL-23 effector proteins in biopsy tissue will be measured.

    Time frame: Baseline, Weeks 12, 24, and 52

07

Study locations

32 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • City of Hope
    Duarte, California 91010, United States
  • Yale University
    New Haven, Connecticut 06519, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • University of Miami
    Miami, Florida 33136, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University School Of Medicine
    Saint Louis, Missouri 63110, United States
  • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
    New York, New York 10032, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Wexner Medical Center at the Ohio State University
    Columbus, Ohio 43210, United States
  • University of Pennsylvania - Perelman School of Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah Huntsman Cancer Institute
    Salt Lake City, Utah 84132, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Hopital Edouard Herriot - CHU Lyon
    Lyon, 69437, France
  • APHM Hopital Timone
    Marseille, 13385, France
  • Universitatsklinikum Bonn
    Bonn, 53127, Germany
  • Universitatsklinikum Ulm
    Ulm, 89070, Germany
  • Sourasky MC
    Tel Aviv, 64239, Israel
  • Academisch Medisch Centrum Universiteit van Amsterdam
    Amsterdam, 1105 AZ, Netherlands
  • Leiden University Medical Center
    Leiden, 2333 ZA, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
  • Szpital Kliniczny im Heliodora Swiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Po
    Poznan, 60 355, Poland
  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
    Warszawa, 02-781, Poland
  • Pan American Center for Oncology Trials LLC
    Rio Piedras, 00935, Puerto Rico
  • Hosp Univ Vall D Hebron
    Barcelona, 8035, Spain
  • Hosp Clinic de Barcelona
    Barcelona, 8036, Spain
  • Karolinska Universitetssjukhuset
    Stockholm, 171 76, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Sep 2021, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2018
First posted
Aug 28, 2018
StartActual
Nov 19, 2018
Primary completionActual
Sep 13, 2021
CompletionActual
Mar 23, 2022
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03649971
Responsible party
Sponsor
First posted
Aug 28, 2018
Start date
Nov 19, 2018
Primary completion
Sep 13, 2021
Completion
Mar 23, 2022
Last update
Feb 3, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion